Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

CMO VP Clinical Development +46 762 788 389
ctg@gesynta.se


Study Location:

Skip to Main Content

Cadwch yn gyfoes

Cofrestrwch i gael newyddion a gwybodaeth am gymryd rhan mewn ymchwil a’i llywio.

English | Cymraeg
Be Part of Research - Trial Details - A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Recruiting

Open to: FEMALE

Age: 18.0 - 44.0

Medical Conditions

Endometriosis


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2025 Jun 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.

Intervention Arm Group : Dose A Vipoglanstat;Dose B Vipoglanstat;

Intervention Type : DRUG
Intervention Description : Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University of Oxford
    Oxford
    OX3 9DU
  • Accellacare North London
    Northwood
    HA6 2RN
  • Accellacare South London
    Orpington
    BR5 3QG
  • Accellacare Warwickshire
    Coventry
    CV3 4FJ
  • Southmead Hospital - North Bristol NHS Trust
    Bristol
    BS10 5NB
  • Southampton General Hospital - University Hospital Southampton NHS Foundation Trust
    Southampton
    SO16 6YD
  • Accellacare Yorkshire
    Bradford
    BD18 3SA
  • Accellacare Northamptonshire
    Corby
    NN18 9EZ
  • Norfolk and Norwich University Hospital - Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich
    NR4 7UY
  • Guy's and St Thomas' NHS Foundation Trust
    London
    SE1 7EH

CMO VP Clinical Development +46 762 788 389
ctg@gesynta.se



The study is sponsored by Gesynta Pharma AB




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT07260669
Last updated 16 April 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.